Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PARP1 | P09874 | 6/20 | 0.50 |
| ▸ | MEP1B | Q16820 | 1/20 | 0.50 |
| ▸ | FOLH1 | Q04609 | 1/20 | 0.47 |
| ▸ | IDH1 | O75874 | 1/20 | 0.46 |
| ▸ | HSD17B1 | P14061 | 1/20 | 0.45 |
| ▸ | CYP4F2 | P78329 | 2/20 | 0.45 |
| ▸ | CYP4A11 | Q02928 | 2/20 | 0.45 |
| ▸ | MEN1 | O00255 | 1/20 | 0.44 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.44 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.42 |
| ▸ | OPRD1 | P41143 | 1/20 | 0.42 |
| ▸ | F10 | P00742 | 2/20 | 0.42 |
| ▸ | KDM1A | O60341 | 1/20 | 0.42 |
| ▸ | MAOA | P21397 | 1/20 | 0.42 |
| ▸ | MAOB | P27338 | 1/20 | 0.42 |
| ▸ | FAAH | O00519 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5645749 | 0.89 | PARP1 (0.53) | PARP1MEP1BFOLH1IDH1HSD17B1 | |
| SCHEMBL7300545 | 0.84 | PARP1 (0.48) | PARP1MEP1BFOLH1IDH1CYP4F2 | |
| SCHEMBL14629791 | 0.84 | CYP4F2 (0.60) | PARP1MEP1BFOLH1IDH1CYP4F2 | |
| SCHEMBL5194309 | 0.83 | SPHK2 (0.52) | PARP1MEP1BFOLH1IDH1CYP4F2 | |
| SCHEMBL7900884 | 0.83 | NOS1 (0.40) | HSD17B1CYP4F2CYP4A11KMT2AF10 | |
| SCHEMBL2108942 | 0.82 | MEP1B (0.59) | PARP1MEP1BFOLH1IDH1MEN1 | |
| SCHEMBL30896294 | 0.82 | MEP1B (0.59) | PARP1MEP1BFOLH1IDH1MEN1 | |
| SCHEMBL10669113 | 0.81 | SPHK2 (0.57) | PARP1CYP4F2CYP4A11 | |
| SCHEMBL8377816 | 0.81 | CYP4F2 (0.48) | PARP1MEP1BFOLH1CYP4F2CYP4A11 | |
| SCHEMBL8342426 | 0.80 | TAAR1 (0.55) | PARP1MEP1BFOLH1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| EP-2226323-A1 | New tetrahydropyrazolo[3,4-c]isoquinolin-5-amine derivatives | Almirall, S.A. (ES) | 2010-09-08 | — | — | EP | disclosed |
| WO-2010097172-A1 | NEW TETRAHYDROPYRAZOLO[3,4-C]ISOQUINOLIN-5-AMINE DERIVATIVES | ALMIRALL, S.A. (ES) | 2010-09-02 | — | — | WO | disclosed |
| EP-0658538-B1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA INC (US) | 1997-10-29 | — | — | EP | disclosed |
| EP-0329464-B1 | System for the closed-loop administration of an exercise simulating agent | GENSIA INC (US) | 1995-11-02 | — | — | EP | disclosed |
| US-5460605-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-10-24 | — | — | US | disclosed |
| EP-0658538-A1 | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA, INC. (US) | 1995-06-21 | — | — | EP | disclosed |
| US-5395970-A | 1-(3,4-dihydroxyphenyl)-2-(4-(4-hydroxyphenyl)butaylamino)ethanol | GENSIA PHARMACEUTICALS, INC. (US) | 1995-03-07 | — | — | US | disclosed |
| US-5286252-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1994-02-15 | — | — | US | disclosed |
| US-5234404-A | Diagnosis, evaluation and treatment of coronary artery disease by exercise simulation using closed loop drug delivery of an exercise simulating agent beta agonist | GENSIA PHARMACEUTICALS, INC. (US) | 1993-08-10 | — | — | US | disclosed |
| US-5108363-A | DIAGNOSIS, EVALUATION AND TREATMENT OF CORONARY ARTERY DISEASE BY EXERCISE SIMULATION USING CLOSED LOOP DRUG DELIVERY OF AN EXERCISE SIMULATING AGENT BETA AGONIST | GENSIA PHARMACEUTICALS, INC. (US) | 1992-04-28 | — | — | US | disclosed |
| EP-0329464-A2 | System for the closed-loop administration of an exercise simulating agent | GENSIA, INC. (US) | 1989-08-23 | — | — | EP | disclosed |